Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) vs 10X Genomics Inc (TXG) Price & Performance

SP Funds S&P 500 Sharia Industry Exclusions ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

SP Funds S&P 500 Sharia Industry Exclusions ETF vs 10X Genomics Inc — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $58.5, while 10X Genomics Inc trades at $67.8 (market cap $8.55B). Which is the better fit depends on your goals.

SPUSTXG
Sector
Broad Market / FactorHealth
52-Week High
$59.51$67.29
52-Week Low
$46.65$11.34
Market Cap
$8.55B
Enterprise Value
$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS trades at $58.72, down 0.53% on the day, with technical indicators showing a neutral to slightly bullish bias. The stock exhibits a narrow trading range with key support and resistance clustered around $58-$59. Recent corporate actions include small quarterly dividends, but key fundamental valuation and profitability ratios are not publicly reported, limiting traditional analysis. No major recent news or earnings data is available to drive sentiment.

The outlook for SPUS is clouded by a lack of accessible fundamental data, presenting a challenge for valuation. The primary opportunity lies in potential undiscovered value, while the significant risk is the inability to assess the company's financial health, earnings power, or competitive position, making it a speculative holding dependent on broader market trends.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.

Read more on SPUS

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG